Chief executive officer Albert Bourla on Tuesday said the clinical trials for its novel coronavirus (COVID-19) vaccine are expected to start next week in the United States, pending approval from health regulators.
“This is a crisis right now, and a solution is desperately needed by all,” Bourla told the Wall Street Journal.
The executive added that results from the study could become available within a month if the trial starts as expected.
If the initial clinical trials are successful, Pfizer could provide the vaccine on an “emergency basis” to the public, and receive approval for widespread distribution by the year’s end, the Journal reported.
“You can imagine the demand for something like that will be extremely, extremely high,” Bourla said.
Pfizer is developing an mRNA vaccine candidate for COVID-19 in partnership with Germany’s BionNTech SE (. Last Wednesday, the two companies announced they received approval from German regulators to start the first COVID-19 vaccine clinical trial in the country.
Pfizer has dedicated about $500 million to its coronavirus drug and vaccine research efforts and another $150 million to increase production capacity, the Journal noted.
What's happening in Tunisia?
Subscribe to our Youtube channel for updates.
